TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY
Kaplan, J., Gordon, L., Infante, J., Popat, R., Rambaldi, A., Madan, S., Patel, M.R., Gritti, G., El-Sharkawi, D., Chau, I., Radford, J., Perez De Oteyza, J., Zinzani, P., Iyer, S., Faucette, S., ShelVolume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2437_60
Date:
June, 2017
File:
PDF, 166 KB
english, 2017